SuperworthPfizer PFE
- Market cap
- $171.2B
- PE
- 39.5×
- 10y median 15.8×
- Forward PE
- 10.9×
- 10y median 12.2×
- Price to sales
- 2.7×
- EV/EBIT
- 14.5×
- Revenue, 12 months
- $63.7B
- −0% on a year ago
- Net margin
- 6.8%
- Free cash flow yield
- 6.4%
Pfizer trades at 39.5× trailing earnings, pricier than 98% of the last ten years. Revenue was $63.7B over the last twelve months, down 0% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.5B−40% | $14.6B−40% | $14.9B−20% | $13.3B+2% | $17.7B+31% | $17.8B+22% | $13.7B−8% | $14.7B+10% | $16.7B−6% | $17.6B−1% | $14.5B+5% | $15B+3% | |
| Cost of revenue | $9.3B+53% | $7.6B−22% | $3.4B−31% | $3.3B+2% | $5.3B−43% | $5.9B−22% | $2.8B−16% | $3.8B+15% | $4.2B−21% | $5.3B−11% | $3.5B+25% | $4.1B+8% |
| Gross profit | $4.2B−75% | $7B−52% | $11.5B−15% | $10B+2% | $12.4B+195% | $11.9B+69% | $10.9B−6% | $10.9B+9% | $12.5B+0% | $12.3B+4% | $10.9B+0% | $10.9B+1% |
| R&D | $2.7B+1% | $2.8B−22% | $2.5B−1% | $2.7B+2% | $2.6B−4% | $3B+8% | $2.2B−12% | $2.5B−8% | $2.5B−2% | $3.2B+6% | $2.5B+13% | $2.8B+13% |
| SG&A | $3.3B−3% | $4.6B−2% | $3.5B+2% | $3.7B+6% | $3.2B−1% | $4.3B−7% | $3B−13% | $3.4B−8% | $3.2B−2% | $4.2B−3% | $3B−2% | $3.4B−0% |
| −$3.2B | −$4.3B | $4.1B−37% | $1B−54% | $5B | $2.3B | $3.7B−9% | $3.8B+277% | $3.9B−22% | $2.9B+22% | $4B+8% | $3.1B−19% | |
| Interest expense | $695M+124% | $688M+120% | $790M+148% | $778M+53% | $783M+13% | $739M+7% | $654M−17% | $654M−16% | $652M−17% | $711M−4% | $668M+2% | $667M+2% |
| Pre-tax income | −$3.4B | −$4.1B | $3.4B−45% | −$103M | $4.7B | −$10M−100% | $2.8B−19% | $3B | $3.3B−29% | −$1.6B+16320% | $3.2B+14% | −$653M |
| −$964M | −$795M | $293M−59% | −$134M+89% | $234M | −$421M−47% | −$189M | $141M | −$216M | −$2M−100% | $461M | −$407M | |
| Net income | −$2.4B | −$3.4B | $3.1B−44% | $41M−98% | $4.5B | $410M | $3B−5% | $2.9B+6998% | $3.5B−21% | −$1.6B | $2.7B−9% | −$248M |
| −$0.42 | −$0.60 | $0.55−43% | $0.01−98% | $0.78 | $0.07 | $0.52−6% | $0.51+5000% | $0.62−21% | −$0.29 | $0.47−10% | −$0.04 | |
| 5.6B−1% | 5.6B−2% | 5.7B−1% | 5.7B−0% | 5.7B+1% | 5.7B+1% | 5.7B+0% | 5.7B+0% | 5.7B+0% | 5.7B−0% | 5.7B+0% | 5.7B−0% |
Gross profit: 72 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 72 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 17 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q3 FY16: the year less its other three quarters as the newest filings print them.
EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent. 17 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: Q4 FY08: share-days: the 12-month average less the 9-month, weighted by days. 17 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $15.9B | $15.5B to $16.2B | $0.73 | $0.68 to $0.81 | 12 |
| Q4 FY26 | $16.9B | $16.6B to $17.3B | $0.71 | $0.63 to $0.75 | 10 |
| Q1 FY27 | $13.9B | $13.6B to $14.6B | $0.68 | $0.66 to $0.72 | 6 |
| Q2 FY27 | $14.3B | $14B to $15B | $0.64 | $0.62 to $0.68 | 6 |
| Q3 FY27 | $15.2B | $14.8B to $15.9B | $0.74 | $0.72 to $0.79 | 6 |
| Q4 FY27 | $16B | $15.6B to $16.8B | $0.64 | $0.62 to $0.68 | 6 |
Peers
Companies in Drug Manufacturers - General nearest Pfizer's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PFEPfizer | $171.2B | 39.5× | 15.8× | 10.9× | 2.7× | −0% | 6.8% |
| GILDGilead Sciences | $193.5B | n/m | 18.8× | 17.2× | 6.4× | +6% | −10.6% |
| BMYBristol-Myers Squibb | $125.6B | 13.5× | 19.9× | 10.4× | 2.6× | +3% | 18.9% |
| AMGNAmgen | $237.5B | 27.3× | 21.1× | 18.6× | 6.2× | +9% | 23.0% |
| MRKMerck | $358.4B | 116× | 24.9× | 17.5× | 5.4× | +5% | 4.8% |
| ABBVAbbVie | $504.8B | 80.7× | 27.9× | 19.0× | 7.8× | +10% | 9.8% |
| JNJJohnson & Johnson | $635.8B | 40.0× | 24.3× | 23.4× | 6.4× | +8% | n/m |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| LLYEli Lilly and | $1.2T | 42.7× | 41.4× | 33.9× | 15.0× | +50% | 33.5% |
| Peer median | $297.9B | 42.7× | 22.7× | 18.8× | 6.3× | +7% | 9.8% |
More on Pfizer
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 33Healthcare stocks with the highest dividend yields
- #3of 51Healthcare stocks with the lowest forward PE
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .